Key Summary
- House of Lords Science and Technology Committee is investigating why the NHS struggles to adopt new medical innovations.
- The inquiry will examine the role of AI and personalised medicine in improving prevention, diagnosis and treatment.
- Experts are invited to submit evidence to help speed up innovation reaching NHS patients.
The House of Lords Science and Technology Committee is launching an inquiry, using personalised medicine and AI as examples, to examine why the NHS adoption of the UK’s cutting-edge life sciences innovations often fails, and what could be done to fix it.
While the advances in artificial intelligence and genomics offer the prospect of developing truly personalised medicine across prevention, diagnosis, and treatment, translating these scientific innovations into routine patient delivery in the NHS remains a challenge.
The house panel will examine the current state of the science underpinning personalised medicine, the major gaps and existing possibilities, including the role of AI in personalised medicine.
What research infrastructure is needed to support the development of personalised medicine and AI in the UK.
How effective the UK is in translating its life sciences strengths into validated personalised medicine and AI tools and what can be done to remain competitive in this field.
How proven innovations might be deployed across the NHS, and what key systematic barriers prevent or delay this.
What the Government needs to do to strengthen feedback loops between medical research, the life sciences industry and the NHS.
The committee has invited written contributions to its inquiry by 20 April 2026.
The committee’s chair, Lord Mair CBE, said, “Our inquiry will use personalised medicine as a case study to explore a broader question: why does the NHS struggle to adopt the UK’s cutting-edge life sciences innovations, and what could be done to fix that?
“As the NHS plans to harness new developments in genomics, AI, and personalised medicine, our inquiry will seek to establish the state of the science and technology in this area and understand where patients might benefit from near-term developments,” he added.
